Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.55 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382141 | 0.85 | ACE (0.40) | ACEMME | |
| SCHEMBL645674 | 0.83 | ACE (0.56) | ACEMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL7088512 | 0.83 | ACE (0.56) | ACEMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL7339985 | 0.83 | ACE (0.56) | ACEMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL7088511 | 0.83 | ACE (0.56) | ACEMMEALDH1A1SMN1; SMN2 | |
| Water SCHEMBL10565338 | 0.82 | ACE (0.54) | ACEMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL7327045 | 0.80 | ACE (0.49) | ACEMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL8277961 | 0.79 | ACE (0.44) | ACEMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL13036956 | 0.79 | ACE (0.41) | ACEMME | |
| SCHEMBL7333578 | 0.78 | ACE (0.76) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009155343-A | NEW OCTAHYDRO-6,10-DIOXO-6H-PYRIDAZINO[1,2-a][1,2]DIAZEPIN-1-CARBOXYLIC ACID DERIVATIVE | AVENTIS PHARMA SA | 2009-07-16 | — | — | JP | disclosed |
| JP-2009155343-A | NEW OCTAHYDRO-6,10-DIOXO-6H-PYRIDAZINO[1,2-a][1,2]DIAZEPIN-1-CARBOXYLIC ACID DERIVATIVE | AVENTIS PHARMA SA | 2009-07-16 | — | — | JP | disclosed |
| US-20030130269-A1 | Derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | AVENTIS PHARMA S.A. | 2003-07-10 | — | — | US | disclosed |
| US-6570012-B2 | Derivatives of octahydro-6, 10-dioxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, useful for preperation of therapeutically active compounds | AVENTIS PHARMA S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
| US-6548664-B1 | Alkylation, hydrogenation, cyclization, condensation, deracemization | AVENTIS PHARMA S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-20020128473-A1 | Derivatives of octahydro-6,10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | AVENTIS PHARMA S.A. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130269-A1 | Derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | CYP2S1, DEGS1, GRIK1 | ACE 2339/4885MME 4613/4885ALDH1A1 575/4885 |
| US-20020128473-A1 | Derivatives of octahydro-6,10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | CYP2D6, THPO, CYP2B6 | ACE 1305/4885MME 3000/4885ALDH1A1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.